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Abstract
Background: Previous data from our laboratory has indicated that a functional link exists between
the G-protein-coupled inwardly rectifying potassium (GIRK) channel and the beta-adrenergic
receptor pathway in breast cancer cell lines, and these pathways were involved in growth regulation
of these cells. Alcohol is an established risk factor for breast cancer and has been found to open
GIRK. In order to further investigate GIRK channels in breast cancer and possible alteration by
ethanol, we identified GIRK channel protein expression in breast cancer cells.
Results: Cell pellets were collected and membrane protein was isolated to determine GIRK
protein expression. GIRK protein was also analyzed by immuno-precipitation. GIRK protein was
over-expressed in cells by transfection of GIRK plasmids. Gene expression studies were done by
real-time RT-PCR. GIRK protein expression was identified in breast cancer cell lines. Expression
of GIRK1 at the indicated molecular weight (MW) (62 kDa) was seen in cell lines MDA-MB-453
and ZR-75-1. In addition, GIRK1 expression was seen at a lower MW (40–42 kDa) in MDA-MB361, MDA-MB-468, MCF-7, ZR-75-1, and MDA-MB-453 cell lines. To prove the lower MW protein
was GIRK1, MDA-MB-453 cells were immuno-precipitated. GIRK2 expression was seen in MDAMB-468, MCF-7, and ZR-75-1 and was variable in MDA-MB-453, while GIRK4 protein expression
was seen in all six cell lines tested. This is the first report indicating GIRK protein expression in
breast cancer cells. To determine functionality, MDA-MB-453 cells were stimulated with ethanol.
Decreased GIRK1 protein expression levels were seen after treatment with 0.12% ethanol in
MDA-MB-453 breast cancer cells. Serum-free media decreased GIRK protein expression, possibly
due to lack of estrogen in the media. Transfection of GIRK1 or GIRK4 plasmids increased GIRK1
protein expression and decreased gene expression in MDA-MB-453 breast cancer cells.
Conclusion: Our data indicates that functional GIRK channels exist in breast cancer cells that are
involved in cellular signaling.

Background
Breast cancer is a leading cancer in women, accounting for
32% of new cancers. It is also the second leading cause of

cancer death for women, and an estimated 211,240 new
cases occurred this year in the USA [1]. Approximately
40% of primary human breast cancers tissues have shown
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In order to further investigate GIRK channels in breast
cancer and possible stimulation by ethanol, we identified
GIRK channel protein expression in breast cancer cells.
Previously we had identified GIRK channel mRNA expression in multiple lung cancer cell lines; however GIRK1
protein expression was seen only in a subset of small cell
lung cancer cell lines [10]. GIRK1 must assemble with
either GIRK2, 3, or 4 to form functional channels because
GIRK1 cannot form channels alone [reviewed in [11]].
Therefore, in the present research, we determined that
breast cancer cell lines express GIRK1, 2, or 4 and that ethanol alters the expression of the protein for these channels.

42 kDa

MDA-MB-361

Ethanol has been shown to increase proliferation and
cAMP levels in two ER (+) cell lines (MCF-7 & ZR-75-1)
but not in ER (-) cell lines (BT-20 & MDA-MB-231) [5].
Although alcohol is an established risk factor for breast
cancer [reviewed in [6] &[7]], little is known of its mechanism of action. Ethanol has been found to open G-protein
inwardly rectifying potassium channels (GIRK) in both
the heart and brain [8], but no effects of ethanol on GIRK
channels in breast cancer have been reported in the literature. However, treatment of MCF-7 breast cancer cells
with ethanol increased ERK1/2 activities and resulted in
subsequent increased cell growth [9].

62 kDa

ZR-75-1

expression of mRNA that encodes a G-protein-coupled
inwardly rectifying potassium channel 1 (GIRK1), and
this expression of GIRK1 was associated with a more
aggressive clinical behavior [2]. Previous data from our
laboratory has indicated that a functional link exists
between the GIRK1 channel and the beta-adrenergic
receptor pathway in breast cancer cell lines, and these
pathways were involved in growth regulation of these cells
[3,4]. The estrogen receptor positive [ER (+)] cell lines
MCF-7, MDA-MB-361, and ZR-75-1 and the ER negative () cell line MDA-MB-453 expressed mRNA for the GIRK1
channel, while the ER (-) cell lines MDA-MB-468 and
MDA-MB-435S did not express GIRK1 [4].
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Figure expression
Protein
1
of GIRK1 in six breast cancer cell lines
Protein expression of GIRK1 in six breast cancer cell
lines. Top panel: GIRK1 expression was shown at the correct molecular weight (62 kDa) in ZR-75-1 and MDA-MB453. GIRK1 expression was also seen at a lower molecular
weight (40–42 kDa) for ZR-75-1, MDA-MB-361, MCF-7,
MDA-MB-468, and MDA-MB-453. Bottom panel: GAPDH
protein was detected in all samples.

determine that this lower MW protein was GIRK1 (Figure
1), we immuno-precipitated two samples of MDA-MB453 with goat polyclonal antibody (Santa Cruz) for
GIRK1, then separated by Western blot and probed with
rabbit polyclonal antibody (Upstate, Lake Placid, NY). In
these immuno-precipitated cells, GIRK1 protein expression was mainly seen at the lower MW (Figure 2). Similar

60 kDa
40 kDa

Results
In order to further investigate the effects of GIRK channels
in breast cancer, expression of GIRK proteins needed to be
determined. Since the predominant GIRK heterotetramers
seem to be GIRK1/2 (brain) and GIRK1/4 (cardiac)
[reviewed in [11] &[12]], we concentrated on GIRK1,
GIRK 2, and GIRK4 expression in these breast cancer cells.
GIRK1 expression was shown at the correct molecular
weight (62 kDa) in ZR-75-1 and MDA-MB-453 (Figure 1).
GIRK1 expression was also seen at a lower molecular
weight (40–42 kDa) for ZR-75-1, MDA-MB-361, MCF-7,
MDA-MB-468, and MDA-MB-453 (Figure 1). Additional
experiments also indicated GIRK1 was also expressed at
the lower MW in MDA-MB-453 cells (data not shown). To

1

2

Immuno-precipitation
tein in Figure
Figure
2
1 was GIRK1
to determine that the lower MW proImmuno-precipitation to determine that the lower
MW protein in Figure 1 was GIRK1. Two samples of
MDA-MB-453 cells were immuno-precipitated with goat polyclonal antibody (Santa Cruz) for GIRK1, then separated by
Western blot, and probed with rabbit polyclonal antibody
used for Figure 1 (Upstate). The highest expression of GIRK1
was at the lower molecular weight in these immuno-precipitated cells. This is a representative gel of two separate
experiments.
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results were seen when MDA-MB-468 cells were immunoprecipitated (data not shown). GIRK1 must assemble with
either GIRK2, 3, or 4 to form functional channels because
GIRK1 cannot form channels alone [reviewed in [11]]. To
determine if the other GIRK channel subunits exist in the
breast cancer cells, we identified GIRK2 and GIRK4
expression. GIRK2 expression was shown at the correct
molecular weight (48–50 kDa) in ZR-75-1, MCF-7, and
MDA-MB-468 (Figure 3). GIRK4 expression was shown at
the correct molecular weight (44 kDa) in all six cell lines
(Figure 3).
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Figure
Protein
cell
linesexpression
3
of GIRK2 and GIRK4 in six breast cancer
Protein expression of GIRK2 and GIRK4 in six breast
cancer cell lines. Top panel: GIRK2 expression was shown
at the correct molecular weight (48–50 kDa) in ZR-75-1,
MCF-7, and MDA-MB-468. Middle panel: GIRK4 expression
was shown at the correct molecular weight (44 kDa) in all six
cell lines. Bottom panel: GAPDH protein was detected in all
samples.
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The majority of our previous research has been done with
the ER (-) breast cancer cell line MDA-MB-453 [4]. Therefore, in the present study we continued using this cell line
for studies on GIRK channel function. To determine if
these GIRK channels are functional, we used ethanol,
which is known to open GIRK channels [8]. GIRK1 protein expression was decreased by 5–30 minute ethanol
treatment (Figure 4), and GIRK1 expression was changed
at both MWs. In addition, both GIRK2 and GIRK4 protein
expression were decreased by 5–30 minute ethanol treatment (Figure 4). Data presented in Figure 3 did not indicate expression of GIRK2 in MDA-MB-453 cells. In these
experiments with ethanol treatment, however GIRK2 was
expressed in MDA-MB-453 cells. Other experiments have
indicated variable expression of GIRK2 in MDA-MB-453
cells (data not shown). This data indicates that expression
of GIRK channels varies during long-term growth of the
cells in culture.

62 kDa

Figure with
Decreases
MDA-MB-453
treated
4 in serum
GIRK1,
cells after
free
GIRK
media
treatment
2, and
for GIRK4
16
with
hours
ethanol
protein(0.12%)
levels inpreDecreases in GIRK1, GIRK 2, and GIRK4 protein levels in MDA-MB-453 cells after treatment with ethanol (0.12%) pre-treated with serum free media for 16
hours. Top panel: GIRK1 protein expression was decreased
by 5–30 minute ethanol treatment. GIRK1 expression was
changed at both MWs. Serum-free media (used in previous
research for 16 hours prior to starting experiment) inhibited
GIRK1 protein expression and was not used after these ethanol experiments. Second panel: GIRK2 protein expression
was decreased by 5–30 minute ethanol treatments. Serumfree media also inhibited GIRK2 protein expression. Third
panel: GIRK4 protein expression was decreased by 5–30
minute ethanol treatment. Serum-free media also decreased
GIRK4 protein expression. Bottom panel: Membranes were
additionally probed with an antibody for actin to ensure
equal loading of protein between samples. This is a representative gel of two separate experiments. Graphs indicate
densitometry of bands, and data are shown as a ratio of
GIRK/actin.

To determine the effects of over-expression of GIRK1 and
GIRK4 on MDA-MB-453 cells, GIRK1 and GIRK4 plasmids were transfected into MDA-MB-453 cells [13].
Increased GIRK1 protein expression was seen in MDAMB-453 breast cancer cells 48 hours after transfection
with GIRK1 or GIRK4 (Figure 5). These bands are also at
the lower MW indicated in Figure 1. On the other hand,
24 hours after transfection of either GIRK1 or GIRK4 plasmids, GIRK1 gene expression was lowered in MDA-MB453 breast cancer cells. GIRK4 expression was decreased
by GIRK1 transfection but increased by GIRK4 transfection. Experiments were performed by real-time RT-PCR
and are expressed as gene-specific CT value-18S control CT
value; mean ± standard deviation. Higher CT values indi-
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sion
transfection
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5 blotwith
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plasmids
breast
an increased
containing
cancer cells
GIRK1
GIRK1
48 protein
hours
or GIRK4
after
expresWestern blot indicates an increased GIRK1 protein
expression in MDA-MB-453 breast cancer cells 48
hours after transfection with plasmids containing
GIRK1 or GIRK4. Top panel: GIRK1 expression; these
bands are at the lower MW (40–42 kDa) indicated in Figure
1. Bottom panel: Membranes were additionally probed with
an antibody for actin to ensure equal loading of protein
between samples. Graph indicates densitometry of bands,
and data are shown as a ratio of GIRK/actin.

cate lower gene expression. GIRK1 gene expression–Control: 16.36 ± 0.53; GIRK1: 18.22 ± 0.52; GIRK4: 18.22 ±
0.12; p < 0.05. GIRK4 gene expression–Control: 19.39 ±
0.61; GIRK1: 21.49 ± 0.02; GIRK4: 16.95 ± 0.78; p < 0.05.
All the above data indicate that the lower MW band in
these cells is GIRK1.
We found that the 16-hour serum-free (SF) media pretreatment normally used for Western blot experiments
largely inhibited GIRK1, GIRK2 and GIRK4 protein
expression in the MDA-MB-453 cells (Figure 4). Therefore, pre-treatment with SF media was not used in experimental treatments described in Figure 5. This decrease in
expression may be due to lack of K+ ions in the media or
to removal of estrogen. In support of this hypothesis,
treatment of the MDA-MB-453 cell line led to an increase
in GIRK1 protein expression after treatment for 24 hours
with charcoal-stripped serum, and GIRK1 levels returned
to control levels with addition of estradiol (Figure 6).
However, we saw a decrease in GIRK protein levels after
48 hours of treatment with estradiol but no change in protein expression in cells treated with charcoal-stripped
serum, indicating that charcoal stripping and estradiol
have different time-dependent effects on MDA-MB-453
cells (Figure 6). To further investigate this decrease in
GIRK1 expression, we incubated MDA-MB-453 for 16
hours (the time that decreased GIRK protein expression)
and found this had no effect on GIRK1 mRNA expression
(data not shown). However, previous data from our laboratory have indicated that 6–7 days of treatment were
needed for β-adrenergic modification of GIRK1 gene

Figure
Western
in
treatment
MDA-MB-453
6blot
withindicates
charcoal-stripped
breastchanges
cancer cells
in serum
GIRK1
24 and
±protein
estradiol
48 hours
expression
after
Western blot indicates changes in GIRK1 protein
expression in MDA-MB-453 breast cancer cells 24
and 48 hours after treatment with charcoal-stripped
serum ± estradiol. Top panel: C=control; CS=charcoalstripped; ES=estradiol. These bands are at the lower MW
(40–42 kDa) indicated in Figure 1. At 24 hours, GIRK1 levels
were increased by charcoal-stripped serum, and were
returned to control levels by estradiol. At 48 hours, GIRK1
levels were unchanged by charcoal-stripped serum, and were
decreased by estradiol. Bottom panel: Membranes were
additionally probed with an antibody for GAPDH to ensure
equal loading of protein between samples. In these experiments, estradiol was dissolved in ethanol (1 mM) and diluted
in water/culture media. In the control and charcoal-stripped
cultures, 10 µl of 1:100 ethanol:water was added, corresponding to the amount of ethanol added to estradiol treated
samples. This is a representative gel of two separate experiments. Graph indicates densitometry of bands, and data are
shown as a ratio of GIRK/GAPDH.

expression in the MDA-MB-453 cells [4]. Therefore the
MDA-MB-453 cell line was grown in SF media for 7 days,
after which real-time PCR revealed decreases in GIRK1
mRNA expression. Data are expressed as described above:
Control: 16.76 ± 0.24; SF: 19.12 ± 0.57; p < 0.007. These
results indicate that both GIRK1 protein and gene expression are inhibited by serum-free conditions.

Discussion
Our previous work has indicated that breast cancer cells
express mRNA for the GIRK channels. Since protein
expression would also be necessary for functional GIRK
channels, we determined GIRK protein expression in the
six breast cancer cell lines. ZR-75-1, MDA-MB-361, MCF7 and MDA-MB-453 express GIRK1 mRNA and protein;
MDA-MB-435S does not express GIRK1 protein or mRNA;
and MDA-MB-468 expresses GIRK1 protein but not
mRNA [4]. In addition, data indicated that mRNA for
GIRK2 was observed in all cell lines except ZR-75-1 and
MDA-MB-435S [4]. GIRK2 protein expression was seen in
MDA-MB-468, MCF-7, and ZR-75-1 and has variable
expression in MDA-MB-453. Gene expression data also
indicated that mRNA for GIRK4 was observed in all cell
lines [4], while GIRK4 protein expression was also seen in
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all six breast cancer cell lines. This is the first report of
GIRK protein in breast cancer cells. We previously first
reported GIRK1 protein was seen in the three small cell
lung cancer (SCLC) cell lines that express GIRK1 mRNA,
and determined GIRK1 protein was not expressed in nonSCLC cell lines [10]. The present data also indicates that
expression of GIRK channels varies during long-term
growth of the cells in culture. This data would correlate
with previous data indicating that expression of GIRK1
was associated with a more aggressive clinical behavior
[2].
Alcohol is an established risk factor for breast cancer
[reviewed in [6] &[7]], but little is known of its mechanism of action. Although treatment of MCF-7 breast cancer cells with ethanol increased ERK1/2 activities and
resulted in subsequent increased cell growth [9], no effects
of ethanol on GIRK channels in breast cancer have been
previously reported in the literature. To determine functionality of the three GIRK channels, MDA-MB-453 cells
were treated with ethanol, which has been found to open
GIRK channels in both the heart and brain [8]. Since the
predominant GIRK heterotetramers seem to be GIRK1/2
and GIRK1/4 [reviewed in [11]], we concentrated on
GIRK1, GIRK2, and GIRK4 expression in these cells.
GIRK1, GIRK2, and GIRK4 protein expression was
decreased by ethanol treatment. We feel that the data indicates that some of the effects of ethanol in breast cancer
may be mediated by GIRK channels. Further research is
needed to determine whether GIRK1/2 or GIRK1/4 is the
predominant heterotetramer in breast cancer. No differences were previously seen between brain-type GIRK1/2
channels and cardiac-type GIRK1/4 channels in their
responses to ethanol treatment [8], and these studies
involved GIRK1/2 and GIRK1/4 transfected into Xenopus
oocytes, an artificial system. It is our hypothesis that the
predominant heterotetramer in MDA-MB-453 breast cancer cells is GIRK1/4, since we see variable expression of
GIRK2 in this cell line.
In our study, GIRK1 was seen at two different molecular
weights in breast cancer cell lines. The higher MW (62
kDa) is indicated on the antibody data sheet. In SCLC cell
lines, we saw expression only at 62 kDa [10]. We believe
that the immuno-precipitation studies likely prove that
the lower MW protein is GIRK1. In addition, ethanol
decreased GIRK1 expression at both MWs. Furthermore,
protein levels of GIRK1 were increased at the lower MW
after overexpression of GIRK1 by transfection studies. This
data indicates that GIRK1 protein is also expressed at a
lower MW in breast cancer cells, a key difference from our
data on small cell lung cancer [10]. We believe some of
this change in MW may be due to long-term growth of the
breast cancer cells in culture also indicating why there is a
difference between the MWs in Figure 1 and Figure 5.

http://www.biomedcentral.com/1472-6793/6/8

It is our contention that the lower MW protein in these
gels is GIRK1 and all the data confirm this lower MW. In
the research, we used two different GIRK1 antibodies, and
the lower MW band appeared in the gels using both antibodies. According to the manufacturer's data sheet
(Upstate Biotechnology, Lake Placid, NY) the antibody
used in Figure 1 corresponded to amino acids 6–42 of rat
GIRK1. As per the manufacturer's data sheet (Santa Cruz,
Santa Cruz, CA), the antibody used in Figures 4–6 was
raised against a peptide within an internal region of
human GIRK1. Since these two antibodies map different
regions, we believe it is unlikely that this is an artifact. In
addition, previous work from our laboratory indicated the
Upstate antibody only appeared at the higher MW in
SCLC cell lines [10]. It is also possible that this lower MW
was a degradation product of GIRK1, but we think this is
unlikely because the same protein samples were used for
determining GIRK2 and GIRK4 protein expression, and
these samples showed no differences in MW. It is our
hypothesis that this lower MW is a splice variant of
GIRK1, since splice variants with truncated versions of
GIRK1 have been previously reported [14]. Further
research is needed in order to confirm this hypothesis.
GIRK1 protein expression was increased by transfection of
GIRK1 and GIRK4 plasmids: however, mRNA expression
of GIRK1 was decreased by transfection of either GIRK1 or
GIRK4. We believe that the increase in GIRK proteins negatively regulates GIRK1 gene expression. It is also our contention that this transfection data confirms previous work
indicating GIRK1 is overexpressed in cancer cells [2]. In
support of this theory, in the present studies, transfection
of GIRK4 leads to an increase in GIRK4 mRNA levels. In
addition, SF media decreased GIRK1 expression. We
believe that this change is due to lack of estrogen in the
media. This is confirmed by our data with charcoalstripped serum and estradiol. Previous investigators have
indicated 17-β-estradiol can modulate GIRK channel activation in the brain, and this modulation is blocked by
protein kinase A and protein kinase C inhibitors [15]. It is
our contention that effects of some risk factors for breast
cancer, such as estrogen and ethanol, can be mediated by
GIRK channels.

Conclusion
Our data indicate that functional GIRK channels that are
involved in cellular signaling exist in breast cancer cells.
Serum free media (used in previous research involving
Western blots for 16 hours prior to starting experiment)
inhibited GIRK1 protein expression, possibly due to lack
of K+ ions or estrogen. These data indicate that the GIRK
channels are functional and an integral part of the intracellular signaling in breast cancer.
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Methods
Cell culture
The human breast cancer cell lines MDA-MB-361, ZR-751, MCF-7, MDA-MB-453, MDA-MB-468, and MDA-MB435S were purchased from the American Type Culture
Collection (Rockville, MD). Cells were maintained in
RPMI 1640 medium supplemented with fetal bovine
serum (10%, v/v), L-glutamine (2 mM), penicillin (100
U/ml), and streptomycin (100 µg/ml) (Mediatech, Herndon, VA) in an environment of 5% CO2.
Chemicals
Estradiol (Sigma St. Louis, MO) was dissolved in ethanol
and diluted in water. Ethanol (100%) was purchased from
AAPER, Shelbyville, KY.
Western blots
Cell pellets were collected and membrane protein was isolated as previously described [10]. Additional antibodies
for GIRK2 and GIRK4 (Santa Cruz, Santa Cruz, CA) were
used in these studies. In some Western blots, membranes
were additionally probed with an antibody for actin
(Sigma) or GAPDH (Abcam, Cambridge, MA) to ensure
equal loading of protein between samples. In the experiment with ethanol treatment (Figure 4) only, cells were
exposed to SF media for 16 hours prior to ethanol treatment. In Figure 6, cells were treated with charcoalstripped serum (Biomeda, Foster City, CA) ± estradiol.
Densitometry was done using Scion Image release Alpha
4.0.3.2, available from NIH.
Transfection studies
We obtained GIRK1 and GIRK4 plasmids (H. Lester, California Institute of Technology) [13] and used Liopofectamine 2000 (Invitrogen, Carlsbad, CA) according to
manufacturer instructions to transfect breast cancer cells
with 10 µg DNA and 20 µl lipofectamine in a 60 mm dish
of cells. Both 24 and 48 hours after transfection, protein
or RNA was isolated from cells.

http://www.biomedcentral.com/1472-6793/6/8

carded. The pellet was gently washed 4 times with 1 ml ice
cold PBS, each time repeating the centrifugation step
above. After the final wash, the supernatant was carefully
aspirated and discarded. The immuno-precipitated pellet
was resuspended in 21 µl of 3× electrophoresis sample
buffer. The samples were boiled for 2 minutes and were
subjected to electrophoresis and autoradiography according to standard methods as previously described [10].
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